Ladenburg raised the firm’s price target on Corcept Therapeutics to $50 from $47.50 and keeps a Buy rating on the shares following the company’s “strong” Q3 report. The firm’s increased price target is based on the strength of the Q3 Korlym results and the increased revenue guidance, the analyst tells investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics price target raised to $34 from $32 at H.C. Wainwright
- Corcept increases FY23 revenue view $470M-$480M from from $455M – $470M
- Corcept Therapeutics reports Q3 EPS 28c, consensus 22c
- Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
- Corcept Therapeutics appoints Monica Tellado as president, emerging markets